Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 816 entries
Sorted by: Best Match Show Resources per page
A Combination of Low Doses of Fluvastatin and Valsartan Decreases Arterial Stiffness in Patients After Myocardial Infarction: A Pilot Study.

Current therapeutic research, clinical and experimental

Hanžel J, Piletič Ž, Turk M, Eržen B, Šabovič M.
PMID: 26199676
Curr Ther Res Clin Exp. 2015 Jun 06;77:63-5. doi: 10.1016/j.curtheres.2015.06.001. eCollection 2015 Dec.

BACKGROUND: Despite optimum treatment, patients who experience myocardial infarction are still at high risk for future events.OBJECTIVE: We evaluated the effect of 30 days of treatment with combination of low, subtherapeutic doses of fluvastatin and valsartan on arterial stiffness...

Cite
Hanžel J, Piletič Ž, Turk M, et al. A Combination of Low Doses of Fluvastatin and Valsartan Decreases Arterial Stiffness in Patients After Myocardial Infarction: A Pilot Study. Curr Ther Res Clin Exp. 2015;77:63-5doi: 10.1016/j.curtheres.2015.06.001.
Hanžel, J., Piletič, �. �., Turk, M., Eržen, B., & Šabovič, M. (2015). A Combination of Low Doses of Fluvastatin and Valsartan Decreases Arterial Stiffness in Patients After Myocardial Infarction: A Pilot Study. Current therapeutic research, clinical and experimental, 7763-5. https://doi.org/10.1016/j.curtheres.2015.06.001
Hanžel, Jurij, et al. "A Combination of Low Doses of Fluvastatin and Valsartan Decreases Arterial Stiffness in Patients After Myocardial Infarction: A Pilot Study." Current therapeutic research, clinical and experimental vol. 77 (2015): 63-5. doi: https://doi.org/10.1016/j.curtheres.2015.06.001
Hanžel J, Piletič Ž, Turk M, Eržen B, Šabovič M. A Combination of Low Doses of Fluvastatin and Valsartan Decreases Arterial Stiffness in Patients After Myocardial Infarction: A Pilot Study. Curr Ther Res Clin Exp. 2015 Jun 06;77:63-5. doi: 10.1016/j.curtheres.2015.06.001. eCollection 2015 Dec. PMID: 26199676; PMCID: PMC4506977.
Copy Download .nbib Format: NLM
Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.

JACC. Heart failure

Di Tano G, Bettari L.
PMID: 28859758
JACC Heart Fail. 2017 Sep;5(9):688-689. doi: 10.1016/j.jchf.2017.06.011.

No abstract available.

Cite
Di Tano G, Bettari L. Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. JACC Heart Fail. 2017;5(9):688-689doi: 10.1016/j.jchf.2017.06.011.
Di Tano, G., & Bettari, L. (2017). Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. JACC. Heart failure, 5(9), 688-689. https://doi.org/10.1016/j.jchf.2017.06.011
Di Tano, Giuseppe, and Bettari, Luca. "Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types." JACC. Heart failure vol. 5,9 (2017): 688-689. doi: https://doi.org/10.1016/j.jchf.2017.06.011
Di Tano G, Bettari L. Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. JACC Heart Fail. 2017 Sep;5(9):688-689. doi: 10.1016/j.jchf.2017.06.011. PMID: 28859758.
Copy Download .nbib Format: NLM
In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients.

Therapeutics and clinical risk management

Zaid AN, Ghanem M, Shweiki D, Shtewi H, Shaheen R, Al Helaly S, Khayyat Z, Al Ramahi R, Zyoud SH.
PMID: 27703364
Ther Clin Risk Manag. 2016 Sep 19;12:1425-1432. doi: 10.2147/TCRM.S110727. eCollection 2016.

OBJECTIVES: The objectives of this study were to evaluate the general quality of the most prescribed products of valsartan (VL; alone or in combination) and to evaluate their efficacy and safety among Palestinian population through in vivo postmarketing surveillance.PATIENTS...

Cite
Zaid AN, Ghanem M, Shweiki D, et al. In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients. Ther Clin Risk Manag. 2016;12:1425-1432doi: 10.2147/TCRM.S110727.
Zaid, A. N., Ghanem, M., Shweiki, D., Shtewi, H., Shaheen, R., Al Helaly, S., Khayyat, Z., Al Ramahi, R., & Zyoud, S. H. (2016). In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients. Therapeutics and clinical risk management, 121425-1432. https://doi.org/10.2147/TCRM.S110727
Zaid, Abdel Naser, et al. "In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients." Therapeutics and clinical risk management vol. 12 (2016): 1425-1432. doi: https://doi.org/10.2147/TCRM.S110727
Zaid AN, Ghanem M, Shweiki D, Shtewi H, Shaheen R, Al Helaly S, Khayyat Z, Al Ramahi R, Zyoud SH. In vitro and in vivo postmarketing surveillance of valsartan, alone or in combination with amlodipine or hydrochlorothiazide, among Palestinian hypertensive patients. Ther Clin Risk Manag. 2016 Sep 19;12:1425-1432. doi: 10.2147/TCRM.S110727. eCollection 2016. PMID: 27703364; PMCID: PMC5036554.
Copy Download .nbib Format: NLM
The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy.

Case reports in cardiology

Gaddipati VC, Patel AA, Cohen AJ.
PMID: 28890834
Case Rep Cardiol. 2017;2017:9561405. doi: 10.1155/2017/9561405. Epub 2017 Aug 14.

Peripartum cardiomyopathy is an uncommon, pregnancy-related form of dilated cardiomyopathy that is associated with development of new-onset left ventricular dysfunction. Its etiology is presently unknown, but current standard of care involves the use of typical drug therapy for the...

Cite
Gaddipati VC, Patel AA, Cohen AJ. The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy. Case Rep Cardiol. 2017;2017:9561405doi: 10.1155/2017/9561405.
Gaddipati, V. C., Patel, A. A., & Cohen, A. J. (2017). The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy. Case reports in cardiology, 20179561405. https://doi.org/10.1155/2017/9561405
Gaddipati, Vamsi C, et al. "The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy." Case reports in cardiology vol. 2017 (2017): 9561405. doi: https://doi.org/10.1155/2017/9561405
Gaddipati VC, Patel AA, Cohen AJ. The Use of a Novel Heart Failure Agent in the Treatment of Pregnancy-Associated Cardiomyopathy. Case Rep Cardiol. 2017;2017:9561405. doi: 10.1155/2017/9561405. Epub 2017 Aug 14. PMID: 28890834; PMCID: PMC5584348.
Copy Download .nbib Format: NLM
The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension.

Journal of the American Society of Hypertension : JASH

Weber MA, Bakris GL, White WB, Xie L, Bharucha D, Patel M.
PMID: 27677146
J Am Soc Hypertens. 2016 Jul;10:e8. doi: 10.1016/j.jash.2016.06.023.

No abstract available.

Cite
Weber MA, Bakris GL, White WB, et al. The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension. J Am Soc Hypertens. 2016;10:e8doi: 10.1016/j.jash.2016.06.023.
Weber, M. A., Bakris, G. L., White, W. B., Xie, L., Bharucha, D., & Patel, M. (2016). The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension. Journal of the American Society of Hypertension : JASH, 10e8. https://doi.org/10.1016/j.jash.2016.06.023
Weber, M A, et al. "The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension." Journal of the American Society of Hypertension : JASH vol. 10 (2016): e8. doi: https://doi.org/10.1016/j.jash.2016.06.023
Weber MA, Bakris GL, White WB, Xie L, Bharucha D, Patel M. The Effects of Nebivolol-Valsartan Single-Pill Combinations in Reducing Blood Pressure in Patients with Stage I or II Hypertension. J Am Soc Hypertens. 2016 Jul;10:e8. doi: 10.1016/j.jash.2016.06.023. PMID: 27677146.
Copy Download .nbib Format: NLM
Effects of Local Pancreatic Renin-Angiotensin System on the Microcirculation of Rat with Severe Acute Pancreatitis.

The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology

Pan Z, Feng L, Long H, Wang H, Feng J, Chen F.
PMID: 26170733
Korean J Physiol Pharmacol. 2015 Jul;19(4):299-307. doi: 10.4196/kjpp.2015.19.4.299. Epub 2015 Jun 30.

Severe acute pancreatitis (SAP) is normally related to multiorgan dysfunction and local complications. Studies have found that local pancreatic renin-angiotensin system (RAS) was significantly upregulated in drug-induced SAP. The present study aimed to investigate the effects of angiotensin II...

Cite
Pan Z, Feng L, Long H, et al. Effects of Local Pancreatic Renin-Angiotensin System on the Microcirculation of Rat with Severe Acute Pancreatitis. Korean J Physiol Pharmacol. 2015;19(4):299-307doi: 10.4196/kjpp.2015.19.4.299.
Pan, Z., Feng, L., Long, H., Wang, H., Feng, J., & Chen, F. (2015). Effects of Local Pancreatic Renin-Angiotensin System on the Microcirculation of Rat with Severe Acute Pancreatitis. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology, 19(4), 299-307. https://doi.org/10.4196/kjpp.2015.19.4.299
Pan, Zhijian, et al. "Effects of Local Pancreatic Renin-Angiotensin System on the Microcirculation of Rat with Severe Acute Pancreatitis." The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology vol. 19,4 (2015): 299-307. doi: https://doi.org/10.4196/kjpp.2015.19.4.299
Pan Z, Feng L, Long H, Wang H, Feng J, Chen F. Effects of Local Pancreatic Renin-Angiotensin System on the Microcirculation of Rat with Severe Acute Pancreatitis. Korean J Physiol Pharmacol. 2015 Jul;19(4):299-307. doi: 10.4196/kjpp.2015.19.4.299. Epub 2015 Jun 30. PMID: 26170733; PMCID: PMC4499641.
Copy Download .nbib Format: NLM
Retraction Note: The effects of valsartan on renal glutathione peroxidase expression in alleviation of cyclosporine nephrotoxicity in rats.

BioImpacts : BI

Raeisi S, Ghorbanihaghjo A, Argani H, Dastmalchi S, Ghasemi B, Ghazizadeh T, Rashtchizadeh N, Mesgari Abbasi M, Bargahi N, Nemati M, Mota A, Vatankhah AM.
PMID: 28265540
Bioimpacts. 2016;6(4):249. doi: 10.15171/bi.2016.31. Epub 2016 Dec 30.

[This retracts the article DOI: 10.15171/bi.2016.18.].

Cite
Raeisi S, Ghorbanihaghjo A, Argani H, et al. Retraction Note: The effects of valsartan on renal glutathione peroxidase expression in alleviation of cyclosporine nephrotoxicity in rats. Bioimpacts. 2016;6(4):249doi: 10.15171/bi.2016.31.
Raeisi, S., Ghorbanihaghjo, A., Argani, H., Dastmalchi, S., Ghasemi, B., Ghazizadeh, T., Rashtchizadeh, N., Mesgari Abbasi, M., Bargahi, N., Nemati, M., Mota, A., & Vatankhah, A. M. (2016). Retraction Note: The effects of valsartan on renal glutathione peroxidase expression in alleviation of cyclosporine nephrotoxicity in rats. BioImpacts : BI, 6(4), 249. https://doi.org/10.15171/bi.2016.31
Raeisi, Sina, et al. "Retraction Note: The effects of valsartan on renal glutathione peroxidase expression in alleviation of cyclosporine nephrotoxicity in rats." BioImpacts : BI vol. 6,4 (2016): 249. doi: https://doi.org/10.15171/bi.2016.31
Raeisi S, Ghorbanihaghjo A, Argani H, Dastmalchi S, Ghasemi B, Ghazizadeh T, Rashtchizadeh N, Mesgari Abbasi M, Bargahi N, Nemati M, Mota A, Vatankhah AM. Retraction Note: The effects of valsartan on renal glutathione peroxidase expression in alleviation of cyclosporine nephrotoxicity in rats. Bioimpacts. 2016;6(4):249. doi: 10.15171/bi.2016.31. Epub 2016 Dec 30. PMID: 28265540; PMCID: PMC5326672.
Copy Download .nbib Format: NLM
Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction.

European heart journal

[No authors listed]
PMID: 28329132
Eur Heart J. 2018 Apr 07;39(14):1180. doi: 10.1093/eurheartj/ehx105.

No abstract available.

Cite
Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction. Eur Heart J. 2018;39(14):1180doi: 10.1093/eurheartj/ehx105.
(2018). Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction. European heart journal, 39(14), 1180. https://doi.org/10.1093/eurheartj/ehx105
"Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction." European heart journal vol. 39,14 (2018): 1180. doi: https://doi.org/10.1093/eurheartj/ehx105
Corrigendum to: Sacubitril/valsartan and low blood pressure in heart failure with reduced ejection fraction. Eur Heart J. 2018 Apr 07;39(14):1180. doi: 10.1093/eurheartj/ehx105. PMID: 28329132.
Copy Download .nbib Format: NLM
Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers.

Intestinal research

Mandavdhare HS, Sharma V, Prasad KK, Kumar A, Rathi M, Rana SS.
PMID: 28670240
Intest Res. 2017 Jul;15(3):419-421. doi: 10.5217/ir.2017.15.3.419. Epub 2017 Jun 12.

Recent studies have identified sprue-like illness associated with the use of the antihypertensive agent olmesartan medoxomil. However, whether this condition is specific to the use of olmesartan or is associated with the use of drugs belonging to the class...

Cite
Mandavdhare HS, Sharma V, Prasad KK, et al. Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers. Intest Res. 2017;15(3):419-421doi: 10.5217/ir.2017.15.3.419.
Mandavdhare, H. S., Sharma, V., Prasad, K. K., Kumar, A., Rathi, M., & Rana, S. S. (2017). Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers. Intestinal research, 15(3), 419-421. https://doi.org/10.5217/ir.2017.15.3.419
Mandavdhare, Harshal Surendra, et al. "Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers." Intestinal research vol. 15,3 (2017): 419-421. doi: https://doi.org/10.5217/ir.2017.15.3.419
Mandavdhare HS, Sharma V, Prasad KK, Kumar A, Rathi M, Rana SS. Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers. Intest Res. 2017 Jul;15(3):419-421. doi: 10.5217/ir.2017.15.3.419. Epub 2017 Jun 12. PMID: 28670240; PMCID: PMC5478768.
Copy Download .nbib Format: NLM
Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients.

International journal of chronic diseases

Ashy N, Nguyen TN, Denhaerynck K, Gharaibeh M, Alhossan A, Vancayzeele S, Brié H, Aerts A, MacDonald K, Abraham I.
PMID: 29142906
Int J Chronic Dis. 2017;2017:9842450. doi: 10.1155/2017/9842450. Epub 2017 Sep 25.

We pooled data from 6 valsartan-related studies including 3,658 diabetic and 11,624 nondiabetic patients to evaluate blood pressure (BP) outcomes after approximately 90 days of second- or later-line valsartan treatment. Hierarchical linear and logistic regressions were applied to identify...

Cite
Ashy N, Nguyen TN, Denhaerynck K, et al. Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. Int J Chronic Dis. 2017;2017:9842450doi: 10.1155/2017/9842450.
Ashy, N., Nguyen, T. N., Denhaerynck, K., Gharaibeh, M., Alhossan, A., Vancayzeele, S., Brié, H., Aerts, A., MacDonald, K., & Abraham, I. (2017). Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. International journal of chronic diseases, 20179842450. https://doi.org/10.1155/2017/9842450
Ashy, Noha, et al. "Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients." International journal of chronic diseases vol. 2017 (2017): 9842450. doi: https://doi.org/10.1155/2017/9842450
Ashy N, Nguyen TN, Denhaerynck K, Gharaibeh M, Alhossan A, Vancayzeele S, Brié H, Aerts A, MacDonald K, Abraham I. Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients. Int J Chronic Dis. 2017;2017:9842450. doi: 10.1155/2017/9842450. Epub 2017 Sep 25. PMID: 29142906; PMCID: PMC5632928.
Copy Download .nbib Format: NLM
Enhanced Protective Effect of the Combination of Uncaria and Semen Raphani on Vascular Endothelium in Spontaneously Hypertensive Rats.

Evidence-based complementary and alternative medicine : eCAM

Li YL, Jiang YH, Yang CH, Sun JC, Wang MM, Yang WQ.
PMID: 26539222
Evid Based Complement Alternat Med. 2015;2015:358352. doi: 10.1155/2015/358352. Epub 2015 Oct 11.

Endothelial dysfunction and low-grade inflammation are closely associated with hypertension and other cardiovascular diseases. The combination of Uncaria (U) and Semen Raphani (R) is common in traditional Chinese medicine for the treatment of hypertension and heart diseases. We aimed...

Cite
Li YL, Jiang YH, Yang CH, et al. Enhanced Protective Effect of the Combination of Uncaria and Semen Raphani on Vascular Endothelium in Spontaneously Hypertensive Rats. Evid Based Complement Alternat Med. 2015;2015:358352doi: 10.1155/2015/358352.
Li, Y. L., Jiang, Y. H., Yang, C. H., Sun, J. C., Wang, M. M., & Yang, W. Q. (2015). Enhanced Protective Effect of the Combination of Uncaria and Semen Raphani on Vascular Endothelium in Spontaneously Hypertensive Rats. Evidence-based complementary and alternative medicine : eCAM, 2015358352. https://doi.org/10.1155/2015/358352
Li, Yun-Lun, et al. "Enhanced Protective Effect of the Combination of Uncaria and Semen Raphani on Vascular Endothelium in Spontaneously Hypertensive Rats." Evidence-based complementary and alternative medicine : eCAM vol. 2015 (2015): 358352. doi: https://doi.org/10.1155/2015/358352
Li YL, Jiang YH, Yang CH, Sun JC, Wang MM, Yang WQ. Enhanced Protective Effect of the Combination of Uncaria and Semen Raphani on Vascular Endothelium in Spontaneously Hypertensive Rats. Evid Based Complement Alternat Med. 2015;2015:358352. doi: 10.1155/2015/358352. Epub 2015 Oct 11. PMID: 26539222; PMCID: PMC4619921.
Copy Download .nbib Format: NLM
Preparation and Evaluation of Valsartan Liquid Filling Formulations for Soft Gels.

Journal of pharmaceutics

Sanaboina J, Maheswari KM, Sunkara S, Deekonda S, Nalluri BN.
PMID: 26555979
J Pharm (Cairo). 2013;2013:418346. doi: 10.1155/2013/418346. Epub 2013 Jan 17.

The present investigation includes the preparation of liquid filling formulations for soft gels using an antihypertensive drug, valsartan (VAL), in order to improve its dissolution properties and thereby its bioavailability. Formulations were prepared using excipients like polyethylene glycol 400...

Cite
Sanaboina J, Maheswari KM, Sunkara S, et al. Preparation and Evaluation of Valsartan Liquid Filling Formulations for Soft Gels. J Pharm (Cairo). 2013;2013:418346doi: 10.1155/2013/418346.
Sanaboina, J., Maheswari, K. M., Sunkara, S., Deekonda, S., & Nalluri, B. N. (2013). Preparation and Evaluation of Valsartan Liquid Filling Formulations for Soft Gels. Journal of pharmaceutics, 2013418346. https://doi.org/10.1155/2013/418346
Sanaboina, Jyothi, et al. "Preparation and Evaluation of Valsartan Liquid Filling Formulations for Soft Gels." Journal of pharmaceutics vol. 2013 (2013): 418346. doi: https://doi.org/10.1155/2013/418346
Sanaboina J, Maheswari KM, Sunkara S, Deekonda S, Nalluri BN. Preparation and Evaluation of Valsartan Liquid Filling Formulations for Soft Gels. J Pharm (Cairo). 2013;2013:418346. doi: 10.1155/2013/418346. Epub 2013 Jan 17. PMID: 26555979; PMCID: PMC4590804.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 816 entries